Company profile
JMackem Co., Ltd.
Privately held: no public share price (A small privately-held South Korean small-molecule drug discovery company (Seoul National University-affiliated), which raised a Series A round in December 2020; no evidence of a public listing/ticker. Not on the roster. Sources: https://clinicaltrials.gov/study/NCT06155487 ; https://api.gleif.org/api/v1/lei-records/984500G84CRC0D4B3920 ; https://api.gleif.org/api/v1/lei-records/984500CE07P48BCA4D79 ; https://www.jmackem.com/en/m13.php ; https://synapse.patsnap.com/organization/3e800ffd8bdd21dfd461bddc5ea1828f Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | —Small molecule | Diabetic Peripheral Neuropathic Pain |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.